We examined 149 lung cancer cell lines for homozygous deletions using 24 DNA markers, which were mapped and ordered in chromosome band 9p21, to define the target regions for 9p21 deletions in human lung cancer. Homozygous deletions were detected in 39 (26%) cell lines and clustered at 2 independent
Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells
✍ Scribed by Andrea R. Florl; Wolfgang A. Schulz
- Book ID
- 102842997
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 672 KB
- Volume
- 37
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The CDKN2A tumor‐suppressor gene in chromosome band 9p21 encoding CDKN2A (also known as p16, INK4A), a negative regulator of cyclin‐dependent kinases, and p14^ARF1^, an activator of TP53, is inactivated in many human cancers by point mutations, promoter hypermethylation, or deletions. Homozygous deletions predominate in certain cancer types (e.g., bladder cancers). To understand why deletions are unusually prevalent at this locus, deletions in bladder and renal cancer cell lines were mapped in detail and several deletion breakpoints cloned. Deletions were interstitial and encompassed 0.1 to >30 Mb. Most deletion breakpoints were located in or close to LINE‐1 retrotransposon clusters. Therefore, deletions of CDKN2A may be facilitated by the presence of LINE‐1 clusters that flank the locus. All cloned junctions were products of non‐homologous recombination and consistently contained exact 2‐bp microhomologies. Microhomologies are otherwise hallmarks of DNA double‐strand break repair by non‐homologous end joining, but the consistent size found at the CDKN2A deletion junctions is difficult to reconcile with the known properties of this process. Therefore, an unknown mechanism appears to be involved in the generation of CDKN2A deletions during carcinogenesis. © 2003 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Homozygous and hemizygous deletions of 9p21 are the earliest and most common genetic alteration in bladder cancer. The identification of two cell cycle regulators, CDKN2 and CDKN2B, that map to the common region of deletion has prompted the hypothesis that they are critical tumor suppressor genes in